Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2011

Open Access 01-12-2011 | Review

Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system

Authors: Anna Vossenkämper, Thomas T MacDonald, Olivier Marchès

Published in: Journal of Inflammation | Issue 1/2011

Login to get access

Abstract

The intestinal immune system and the epithelium are the first line of defense in the gut. Constantly exposed to microorganisms from the environment, the gut has complex defense mechanisms to prevent infections, as well as regulatory pathways to tolerate commensal bacteria and food antigens. Intestinal pathogens have developed strategies to regulate intestinal immunity and inflammation in order to establish or prolong infection. The organisms that employ a type III secretion system use a molecular syringe to deliver effector proteins into the cytoplasm of host cells. These effectors target the host cell cytoskeleton, cell organelles and signaling pathways. This review addresses the multiple mechanisms by which the type III secretion system targets the intestinal immune response, with a special focus on pathogenic E. coli.
Appendix
Available only for authorised users
Literature
1.
Castro GA, Arntzen CJ: Immunophysiology of the gut: a research frontier for integrative studies of the common mucosal immune system. Am J Physiol. 1993, 265: G599-610.PubMed
2.
3.
MacDonald T: The gut is still the biggest lymphoid organ in the body. Mucosal Immunology. 2008, 1: 246-247.CrossRef
4.
Neutra MR, Mantis NJ, Kraehenbuhl JP: Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol. 2001, 2: 1004-1009. 10.1038/ni1101-1004.PubMedCrossRef
5.
Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl JP, Ricciardi-Castagnoli P: Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001, 2: 361-367. 10.1038/86373.PubMedCrossRef
6.
Gorfu G, Rivera-Nieves J, Ley K: Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med. 2009, 9: 836-850. 10.2174/156652409789105525.PubMedPubMedCentralCrossRef
7.
Cunliffe RN, Mahida YR: Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J Leukoc Biol. 2004, 75: 49-58.PubMedCrossRef
8.
Plaut AG: Trefoil peptides in the defense of the gastrointestinal tract. N Engl J Med. 1997, 336: 506-507. 10.1056/NEJM199702133360712.PubMedCrossRef
9.
Kim YS, Ho SB: Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010, 12: 319-330. 10.1007/s11894-010-0131-2.PubMedPubMedCentralCrossRef
10.
Cerf-Bensussan N, Gaboriau-Routhiau V: The immune system and the gut microbiota: friends or foes?. Nat Rev Immunol. 2010, 10: 735-744. 10.1038/nri2850.PubMedCrossRef
11.
Macpherson AJ, Hunziker L, McCoy K, Lamarre A: IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect. 2001, 3: 1021-1035. 10.1016/S1286-4579(01)01460-5.PubMedCrossRef
12.
Suzuki K, Maruya M, Kawamoto S, Sitnik K, Kitamura H, Agace WW, Fagarasan S: The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity. 2010, 33: 71-83. 10.1016/j.immuni.2010.07.003.PubMedCrossRef
13.
Spencer J, Barone F, Dunn-Walters D: Generation of Immunoglobulin diversity in human gut-associated lymphoid tissue. Semin Immunol. 2009, 21: 139-146. 10.1016/j.smim.2009.01.003.PubMedCrossRef
14.
Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P: The immune geography of IgA induction and function. Mucosal Immunol. 2008, 1: 11-22. 10.1038/mi.2007.6.PubMedCrossRef
15.
Maizels RM, Yazdanbakhsh M: Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol. 2003, 3: 733-744. 10.1038/nri1183.PubMedCrossRef
16.
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, Doherty JM, Mills JC, Colonna M: A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009, 457: 722-725. 10.1038/nature07537.PubMedPubMedCentralCrossRef
17.
Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, Matuzaki Y, Suzuki S, Sugita A, Koganei K, Hisamatsu T, Kanai T, Hibi T: Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology. 2010, 139: 882-892. 10.1053/j.gastro.2010.05.040. 892 e881-883PubMedCrossRef
18.
Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, Mention JJ, Thiam K, Cerf-Bensussan N, Mandelboim O, Eberl G, Di Santo JP: Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity. 2008, 29: 958-970. 10.1016/j.immuni.2008.11.001.PubMedCrossRef
19.
Shiomi H, Masuda A, Nishiumi S, Nishida M, Takagawa T, Shiomi Y, Kutsumi H, Blumberg RS, Azuma T, Yoshida M: Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection. Infect Immun. 2010, 78: 2653-2666. 10.1128/IAI.01343-09.PubMedPubMedCentralCrossRef
20.
Jabri B, Ebert E: Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Immunol Rev. 2007, 215: 202-214. 10.1111/j.1600-065X.2006.00481.x.PubMedCrossRef
21.
Beagley KW, Husband AJ: Intraepithelial lymphocytes: origins, distribution, and function. Crit Rev Immunol. 1998, 18: 237-254.PubMedCrossRef
22.
Sanz Y, De Palma G: Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. Int Rev Immunol. 2009, 28: 397-413. 10.3109/08830180903215613.PubMedCrossRef
23.
Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC, Pulendran B: Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010, 329: 849-853. 10.1126/science.1188510.PubMedPubMedCentralCrossRef
24.
Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010, 11: 373-384. 10.1038/ni.1863.PubMedCrossRef
25.
Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 2000, 408: 740-745. 10.1038/35047123.PubMedCrossRef
26.
Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, Han SH, Lee H, Paik SG, Lee JO: Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity. 2009, 31: 873-884. 10.1016/j.immuni.2009.09.018.PubMedCrossRef
27.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001, 411: 599-603. 10.1038/35079107.PubMedCrossRef
28.
Keshet Y, Seger R: The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010, 661: 3-38. 10.1007/978-1-60761-795-2_1.PubMedCrossRef
29.
Malladi V, Puthenedam M, Williams PH, Balakrishnan A: Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-kappaB and MAP kinases. Inflammation. 2004, 28: 345-353. 10.1007/s10753-004-6645-8.PubMedCrossRef
30.
Shames SR, Auweter SD, Finlay BB: Co-evolution and exploitation of host cell signaling pathways by bacterial pathogens. Int J Biochem Cell Biol. 2009, 41: 380-389. 10.1016/j.biocel.2008.08.013.PubMedCrossRef
31.
Sasakawa C: A new paradigm of bacteria-gut interplay brought through the study of Shigella. Proc Jpn Acad Ser B Phys Biol Sci. 2010, 86: 229-243. 10.2183/pjab.86.229.PubMedPubMedCentralCrossRef
32.
Kim M, Ashida H, Ogawa M, Yoshikawa Y, Mimuro H, Sasakawa C: Bacterial interactions with the host epithelium. Cell Host Microbe. 2010, 8: 20-35. 10.1016/j.chom.2010.06.006.PubMedCrossRef
33.
Macdonald TT, Monteleone G: Immunity, inflammation, and allergy in the gut. Science. 2005, 307: 1920-1925. 10.1126/science.1106442.PubMedCrossRef
34.
Iwai H, Kim M, Yoshikawa Y, Ashida H, Ogawa M, Fujita Y, Muller D, Kirikae T, Jackson PK, Kotani S, Sasakawa C: A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling. Cell. 2007, 130: 611-623. 10.1016/j.cell.2007.06.043.PubMedCrossRef
35.
Kim M, Ogawa M, Fujita Y, Yoshikawa Y, Nagai T, Koyama T, Nagai S, Lange A, Fassler R, Sasakawa C: Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment. Nature. 2009, 459: 578-582. 10.1038/nature07952.PubMedCrossRef
36.
Tobe T, Beatson SA, Taniguchi H, Abe H, Bailey CM, Fivian A, Younis R, Matthews S, Marches O, Frankel G, Hayashi T, Pallen MJ: An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci USA. 2006, 103: 14941-14946. 10.1073/pnas.0604891103.PubMedPubMedCentralCrossRef
37.
Muenzner P, Bachmann V, Zimmermann W, Hentschel J, Hauck CR: Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation. Science. 2010, 329: 1197-1201. 10.1126/science.1190892.PubMedCrossRef
38.
Marches O, Ledger TN, Boury M, Ohara M, Tu X, Goffaux F, Mainil J, Rosenshine I, Sugai M, De Rycke J, Oswald E: Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol Microbiol. 2003, 50: 1553-1567. 10.1046/j.1365-2958.2003.03821.x.PubMedCrossRef
39.
Jubelin G, Taieb F, Duda DM, Hsu Y, Samba-Louaka A, Nobe R, Penary M, Watrin C, Nougayrede JP, Schulman BA, Stebbins CE, Oswald E: Pathogenic bacteria target NEDD8-conjugated cullins to hijack host-cell signaling pathways. PLoS Pathog. 2010, 6:
40.
Samba-Louaka A, Nougayrede JP, Watrin C, Jubelin G, Oswald E, Taieb F: Bacterial cyclomodulin Cif blocks the host cell cycle by stabilizing the cyclin-dependent kinase inhibitors p21 and p27. Cell Microbiol. 2008, 10: 2496-2508. 10.1111/j.1462-5822.2008.01224.x.PubMedCrossRef
41.
Shames SR, Deng W, Guttman JA, de Hoog CL, Li Y, Hardwidge PR, Sham HP, Vallance BA, Foster LJ, Finlay BB: The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling. Cell Microbiol. 2010, 12: 1322-1339. 10.1111/j.1462-5822.2010.01470.x.PubMedCrossRef
42.
Hemrajani C, Berger CN, Robinson KS, Marches O, Mousnier A, Frankel G: NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proc Natl Acad Sci USA. 2010, 107: 3129-3134. 10.1073/pnas.0911609106.PubMedPubMedCentralCrossRef
43.
Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, Yogev O, Shaulian E, Guttman C, Zarivach R, Rosenshine I: Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. Embo J. 2010, 30: 221-231.PubMedPubMedCentralCrossRef
44.
Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vazquez A, Barba J, Ibarra JA, O'Donnell P, Metalnikov P, Ashman K, Lee S, Goode D, Pawson T, Finlay BB: Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci USA. 2004, 101: 3597-3602. 10.1073/pnas.0400326101.PubMedPubMedCentralCrossRef
45.
Kelly M, Hart E, Mundy R, Marches O, Wiles S, Badea L, Luck S, Tauschek M, Frankel G, Robins-Browne RM, Hartland EL: Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium. Infect Immun. 2006, 74: 2328-2337. 10.1128/IAI.74.4.2328-2337.2006.PubMedPubMedCentralCrossRef
46.
Marches O, Wiles S, Dziva F, La Ragione RM, Schuller S, Best A, Phillips AD, Hartland EL, Woodward MJ, Stevens MP, Frankel G: Characterization of two non-locus of enterocyte effacement-encoded type III-translocated effectors, NleC and NleD, in attaching and effacing pathogens. Infect Immun. 2005, 73: 8411-8417. 10.1128/IAI.73.12.8411-8417.2005.PubMedPubMedCentralCrossRef
47.
Bhavsar AP, Guttman JA, Finlay BB: Manipulation of host-cell pathways by bacterial pathogens. Nature. 2007, 449: 827-834. 10.1038/nature06247.PubMedCrossRef
48.
Petty NK, Bulgin R, Crepin VF, Cerdeno-Tarraga AM, Schroeder GN, Quail MA, Lennard N, Corton C, Barron A, Clark L, Toribio AL, Parkhill J, Dougan G, Frankel G, Thomson NR: The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli. J Bacteriol. 2010, 192: 525-538. 10.1128/JB.01144-09.PubMedPubMedCentralCrossRef
49.
Garmendia J, Frankel G, Crepin VF: Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation. Infect Immun. 2005, 73: 2573-2585. 10.1128/IAI.73.5.2573-2585.2005.PubMedPubMedCentralCrossRef
50.
Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P: Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun. 2001, 69: 1298-1305. 10.1128/IAI.69.3.1298-1305.2001.PubMedPubMedCentralCrossRef
51.
Ramirez K, Huerta R, Oswald E, Garcia-Tovar C, Hernandez JM, Navarro-Garcia F: Role of EspA and intimin in expression of proinflammatory cytokines from enterocytes and lymphocytes by rabbit enteropathogenic Escherichia coli-infected rabbits. Infect Immun. 2005, 73: 103-113. 10.1128/IAI.73.1.103-113.2005.PubMedPubMedCentralCrossRef
52.
Ruchaud-Sparagano MH, Maresca M, Kenny B: Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function. Cell Microbiol. 2007, 9: 1909-1921. 10.1111/j.1462-5822.2007.00923.x.PubMedPubMedCentralCrossRef
53.
Sharma R, Tesfay S, Tomson FL, Kanteti RP, Viswanathan VK, Hecht G: Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G685-694. 10.1152/ajpgi.00404.2005.PubMedCrossRef
54.
Mumy KL, McCormick BA: The role of neutrophils in the event of intestinal inflammation. Curr Opin Pharmacol. 2009, 9: 697-701. 10.1016/j.coph.2009.10.004.PubMedPubMedCentralCrossRef
55.
Gao X, Wan F, Mateo K, Callegari E, Wang D, Deng W, Puente J, Li F, Chaussee MS, Finlay BB, Lenardo MJ, Hardwidge PR: Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog. 2009, 5: e1000708-10.1371/journal.ppat.1000708.PubMedPubMedCentralCrossRef
56.
Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L, Hegde V, Lam LT, Staudt LM, Levens D, Deutsch WA, Lenardo MJ: Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell. 2007, 131: 927-939. 10.1016/j.cell.2007.10.009.PubMedCrossRef
57.
Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C: The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA. 2005, 102: 14046-14051. 10.1073/pnas.0504466102.PubMedPubMedCentralCrossRef
58.
Royan SV, Jones RM, Koutsouris A, Roxas JL, Falzari K, Weflen AW, Kim A, Bellmeyer A, Turner JR, Neish AS, Rhee KJ, Viswanathan VK, Hecht GA: Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation. Mol Microbiol. 2010, 78: 1232-1245. 10.1111/j.1365-2958.2010.07400.x.PubMedPubMedCentralCrossRef
59.
Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, Henderson IR, Harris D, Asadulghani M, Kurokawa K, Dean P, Kenny B, Quail MA, Thurston S, Dougan G, Hayashi T, Parkhill J, Frankel G: Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69. J Bacteriol. 2009, 191: 347-354. 10.1128/JB.01238-08.PubMedPubMedCentralCrossRef
60.
Wickham ME, Lupp C, Mascarenhas M, Vazquez A, Coombes BK, Brown NF, Coburn BA, Deng W, Puente JL, Karmali MA, Finlay BB: Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection. J Infect Dis. 2006, 194: 819-827. 10.1086/506620.PubMedCrossRef
61.
Newton HJ, Pearson JS, Badea L, Kelly M, Lucas M, Holloway G, Wagstaff KM, Dunstone MA, Sloan J, Whisstock JC, Kaper JB, Robins-Browne RM, Jans DA, Frankel G, Phillips AD, Coulson BS, Hartland EL: The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog. 2010, 6: e1000898-10.1371/journal.ppat.1000898.PubMedPubMedCentralCrossRef
62.
Muhlen S, Ruchaud-Sparagano MH, Kenny B: Proteasome-independent Degradation of Canonical NF{kappa}B Complex Components by the NleC Protein of Pathogenic Escherichia coli. J Biol Chem. 2010, 286: 5100-5107.PubMedPubMedCentralCrossRef
63.
Pearson JS, Riedmaier P, Marches O, Frankel G, Hartland EL: A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol. 2010
64.
Yen H, Ooka T, Iguchi A, Hayashi T, Sugimoto N, Tobe T: NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog. 2010, 6: e1001231-10.1371/journal.ppat.1001231.PubMedPubMedCentralCrossRef
65.
Zurawski DV, Mumy KL, Badea L, Prentice JA, Hartland EL, McCormick BA, Maurelli AT: The NleE/OspZ family of effector proteins is required for polymorphonuclear transepithelial migration, a characteristic shared by enteropathogenic Escherichia coli and Shigella flexneri infections. Infect Immun. 2008, 76: 369-379. 10.1128/IAI.00684-07.PubMedPubMedCentralCrossRef
66.
Wickham ME, Lupp C, Vazquez A, Mascarenhas M, Coburn B, Coombes BK, Karmali MA, Puente JL, Deng W, Finlay BB: Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE. Microbes Infect. 2007, 9: 400-407. 10.1016/j.micinf.2006.12.016.PubMedCrossRef
67.
Deng W, de Hoog CL, Yu HB, Li Y, Croxen MA, Thomas NA, Puente JL, Foster LJ, Finlay BB: A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium. J Biol Chem. 2010, 285: 6790-6800. 10.1074/jbc.M109.086603.PubMedPubMedCentralCrossRef
68.
Nadler C, Baruch K, Kobi S, Mills E, Haviv G, Farago M, Alkalay I, Bartfeld S, Meyer TF, Ben-Neriah Y, Rosenshine I: The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog. 2010, 6: e1000743-10.1371/journal.ppat.1000743.PubMedPubMedCentralCrossRef
69.
Vossenkamper A, Marches O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong le A, Croft NM, Naik S, Frankel G, MacDonald TT: Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol. 2010, 185: 4118-4127. 10.4049/jimmunol.1000500.PubMedCrossRef
70.
Fitzhenry RJ, Reece S, Trabulsi LR, Heuschkel R, Murch S, Thomson M, Frankel G, Phillips AD: Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup. Infect Immun. 2002, 70: 4362-4368. 10.1128/IAI.70.8.4362-4368.2002.PubMedPubMedCentralCrossRef
71.
Caron E, Hall A: Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science. 1998, 282: 1717-1721.PubMedCrossRef
72.
Celli J, Olivier M, Finlay BB: Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways. EMBO J. 2001, 20: 1245-1258. 10.1093/emboj/20.6.1245.PubMedPubMedCentralCrossRef
73.
Dong N, Liu L, Shao F: A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis. EMBO J. 2010, 29: 1363-1376. 10.1038/emboj.2010.33.PubMedPubMedCentralCrossRef
74.
Iizumi Y, Sagara H, Kabe Y, Azuma M, Kume K, Ogawa M, Nagai T, Gillespie PG, Sasakawa C, Handa H: The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function. Cell Host Microbe. 2007, 2: 383-392. 10.1016/j.chom.2007.09.012.PubMedCrossRef
75.
Marches O, Covarelli V, Dahan S, Cougoule C, Bhatta P, Frankel G, Caron E: EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. Cell Microbiol. 2008, 10: 1104-1115. 10.1111/j.1462-5822.2007.01112.x.PubMedPubMedCentralCrossRef
76.
Martinez-Argudo I, Sands C, Jepson MA: Translocation of enteropathogenic Escherichia coli across an in vitro M cell model is regulated by its type III secretion system. Cell Microbiol. 2007, 9: 1538-1546. 10.1111/j.1462-5822.2007.00891.x.PubMedCrossRef
77.
Quitard S, Dean P, Maresca M, Kenny B: The enteropathogenic Escherichia coli EspF effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting. Cell Microbiol. 2006, 8: 972-981. 10.1111/j.1462-5822.2005.00680.x.PubMedCrossRef
78.
Holmes A, Muhlen S, Roe AJ, Dean P: The EspF effector, a bacterial pathogen's Swiss army knife. Infect Immun. 2010, 78: 4445-4453. 10.1128/IAI.00635-10.PubMedPubMedCentralCrossRef
79.
Weflen AW, Alto NM, Viswanathan VK, Hecht G: E. coli secreted protein F promotes EPEC invasion of intestinal epithelial cells via an SNX9-dependent mechanism. Cell Microbiol. 2010, 12: 919-929. 10.1111/j.1462-5822.2010.01440.x.PubMedPubMedCentralCrossRef
80.
Selyunin AS, Sutton SE, Weigele BA, Reddick LE, Orchard RC, Bresson SM, Tomchick DR, Alto NM: The assembly of a GTPase-kinase signalling complex by a bacterial catalytic scaffold. Nature. 2011, 469: 107-111. 10.1038/nature09593.PubMedPubMedCentralCrossRef
81.
Niedergang F, Colucci-Guyon E, Dubois T, Raposo G, Chavrier P: ADP ribosylation factor 6 is activated and controls membrane delivery during phagocytosis in macrophages. J Cell Biol. 2003, 161: 1143-1150. 10.1083/jcb.200210069.PubMedPubMedCentralCrossRef
82.
Maddocks OD, Short AJ, Donnenberg MS, Bader S, Harrison DJ: Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One. 2009, 4: e5517-10.1371/journal.pone.0005517.PubMedPubMedCentralCrossRef
83.
Spehlmann ME, Dann SM, Hruz P, Hanson E, McCole DF, Eckmann L: CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen. J Immunol. 2009, 183: 3332-3343. 10.4049/jimmunol.0900600.PubMedPubMedCentralCrossRef
Metadata
Title
Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system
Authors
Anna Vossenkämper
Thomas T MacDonald
Olivier Marchès
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2011
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-8-11

Other articles of this Issue 1/2011

Journal of Inflammation 1/2011 Go to the issue

Research

Zinc supplementation alters airway inflammation and airway hyperresponsiveness to a common allergen

Research

Insulin augments tumor necrosis factor-alpha stimulated expression of vascular cell adhesion molecule-1 in vascular endothelial cells

Research

Histological and ultrastructural comparison of cauterization and thrombosis stroke models in immune-deficient mice

Research

Histology of adipose tissue inflammation in Dercum's disease, obesity and normal weight controls: a case control study

Research

Antioxidant and potential anti-inflammatory activity of extracts and formulations of white tea, rose, and witch hazel on primary human dermal fibroblast cells

Research

Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits